Recently, Dr. Bu Guojun, Director of the Division of Life Science and Chair Professor endowed by the Lo Ka Chung Charitable Foundation at the Hong Kong University of Science and Technology (HKUST), visited Deep Harbour Cell Valley. Professor Shi Yuanyuan, Founder of Deep Harbour Cell Valley, along with Dr. David Jin, Chief Medical Officer,  Professor Wang Jianxun, Chief Scientist, Dr. Fu Yuchen, Assistant to the Chairman, and Sun Rui, Director of the Marketing Department, warmly received him and engaged in in-depth discussions with  Professor Bu on cutting-edge life science research and industrial translation.

Professor Bu Guojun is a top-tier scholar in the international fields of neuroscience and biomedical research. He has long been dedicated to studying the mechanisms of the Low-Density Lipoprotein Receptor (LDLR) family in cholesterol metabolism and neurodegenerative diseases, such as Alzheimer's disease. Previously, he served as the Chair of the Department of Neuroscience and Deputy Director of the Alzheimer's Disease Research Center at the Mayo Clinic in the United States, making him one of the few Chinese scholars to hold a department chair position at a world-class international institution.

(Screenshot of Professor Bu Guojun's profile on the HKUST official website)

Accompanied by Professor Shi Yuanyuan, Professor Bu toured the Smart Exhibition Hall of Deep Harbour Cell Valley. He gained a detailed understanding of the company's technology platforms, scientific research achievements, and clinical translation applications in the field of gene and cell therapy. He spoke highly of the company's systematic layout and innovative breakthroughs in industrial implementation.

During the symposium, Professor Shi Yuanyuan introduced the overall development strategy of Deep Harbour Cell Valley. He focused on elaborating the company's full-chain capabilities built around viral vectors, cell preparation, GMP production, clinical trials, and technology translation. The company has now established collaborations with over 80 Grade-A Tertiary hospitals nationwide and has extensively deployed product lines including CAR-T, CAR-NK, Natural Killer (NK) cells, Mesenchymal Stem Cells (MSC), and Exosomes, serving diverse clinical needs in oncology, immune diseases, and anti-aging.

Professor Bu Guojun shared the latest progress of HKUST in basic life science research and pointed out that industry-academia-research collaboration is the key pathway to advancing cell and gene therapy into clinical practice. Professor Bu stated that while HKUST possesses outstanding advantages in frontier basic research,  Deep Harbour Cell Valley has deep accumulation in achievement translation and industrialization.  The two sides have broad prospects for cooperation in research on major diseases such as Alzheimer's disease, and look forward to jointly tackling key technologies, promoting high-quality development of the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area, and benefiting human health.